Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society

BACKGROUND: There is an increasing interest in HER2-low breast cancer with promising data from clinical trials using novel anti-HER2 antibody–drug conjugates. We explored the differences in clinicopathological characteristics and survival outcomes between HER2-low and HER2-IHC 0 breast cancer. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Won, Hye Sung, Ahn, Juneyoung, Kim, Yongseon, Kim, Jin Sung, Song, Jeong-Yoon, Kim, Hong-Kyu, Lee, Jeeyeon, Park, Heung Kyu, Kim, Yong-Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935777/
https://www.ncbi.nlm.nih.gov/pubmed/35307014
http://dx.doi.org/10.1186/s13058-022-01519-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935777/
https://www.ncbi.nlm.nih.gov/pubmed/35307014
http://dx.doi.org/10.1186/s13058-022-01519-x

Ejemplares similares